Back to results
US 2019/0315882 A1Published application
Affinity maturated tag72 specific single chain antibodies
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorHatem Soliman
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, affinity maturated single chain variable fragment (scFv) antibodies that bind TAG-72 on cancer cells are disclosed.
Claims17
A single chain variable fragment (scFv) TAG-72 antibody, comprising a variable heavy (VH) domain having CDR1, CDR2 and CDR3 sequences and a variable light (VL) domain having CDR1, CDR2 and CDR3 sequences,
- wherein the CDR1 sequence of the VH domain comprises the amino acid sequence DHAIH (SEQ ID NO:1),
- wherein the CDR2 sequence of the VH domain has an amino acid sequence selected from the group consisting of WIGYFSPGNDDFRYNERFKG (SEQ ID NO:3), WIGYFSPGNDDFKYNERYKG (SEQ ID NO:4), and WIGYFSPGNNDFKYNERFKG (SEQ ID NO:5),
- wherein the CDR3 sequence of the VH domain comprises the amino acid sequence LNMAY (SEQ ID NO:2),
- wherein the CDR1 sequence of the VL domain has an amino acid sequence selected from the group consisting of KSSQSLLYSGNQKNYLA (SEQ ID NO:9) and KSSQSLLYSGNHKNYLA (SEQ ID NO:12),
- wherein the CDR2 sequence of the VL domain comprises the amino acid sequence WASARES (SEQ ID NO:10), and
- wherein the CDR3 sequence of the VL domain comprises the amino acid sequence KSSQSLLYSGNHKNYLA (SEQ ID NO:12),
- wherein when the CDR2 sequence of the VH domain has the amino acid sequence SEQ ID NO:3, the CDR1 sequence of the VL domain has the amino acid sequence SEQ ID NO:12.
4 more elements
Dependencies are inferred from the claim text.